Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program
Saved in:
| Published in: | Biologics: Targets & Therapy |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|